Management of peritoneal surface malignancy with cytoreductive surgery and perioperative intraperitoneal chemotherapy
Introduction
Peritoneal carcinomatosis has long been considered incurable. Despite the development of new, more effective chemotherapeutic agents and combinations, the results of systemic chemotherapy treatment remain disappointing, with a limited impact on survival. Patients with peritoneal carcinomatosis have long been considered as a terminal condition with no curative options. The natural history of untreated patients with this condition showed a median survival ranging between 3 and 9 months depending on the primary tumor involved.1, 2, 3, 4 There is a renewed interest in peritoneal surface malignancies with a new therapeutic strategy towards peritoneal carcinomatosis being developed over the past 20 years combining maximum radical cytoreductive surgery and perioperative intraperitoneal chemotherapy. Some interesting results have been reported although a majority of oncologists remains skeptical regarding this combined therapeutic approach.5, 6 To provide further data, a collaborative effort of the Spanish institutions involved in the treatment of peritoneal surface malignancies gathered information on a large number of patients to evaluate the efficacy of this treatment, and to identify principal prognostic indicators. The aim of this study is to present the preliminary results of the Spanish national experience of the main groups involved in this new treatment alternative.
Section snippets
Patients and methods
A retrospective multicenter study was performed to evaluate the national experience with this combined treatment strategy and to identify the principal prognostic indicators.
During the months of April and June 2004, a questionnaire was sent out nationally to all the General Surgery and Digestive Tract departments of the hospital centers in Spain interested in this problem.
A data sheet was enclosed, with the date of July 31, 2004 as the limit for including patients and September 30 as the limit
Data forms
A standard data form was created to retrieve information on the primary tumor including its location, the presence or absence of hepatic or lymphatic metastases, and the differentiation of the primary tumor. The form also recorded information on the status of the patient before undergoing the combined procedure, including the sex, the age, the extent of peritoneal carcinomatosis, and the previous treatment with systemic chemotherapy. The extent of peritoneal carcinomatosis was assessed by
Statistical analysis
Analysis was performed up to July 2004. Data were recorded and analyzed with a commercially available computer program (SPSS 12.0 for Windows. The Apache Software Foundation, USA). To study relationships between variables, standard tests have been used: Chi-square with 2 variables, Pearson's correlation (or Spearman's ranks correlation) if quantitative, and analysis of variance, Student's t-test, otherwise Kruskall–Wallis H-test, depending on the number of distributions, normality, and
Clinico-pathological data
The study includes 266 patients from 9 National Institutions operated on between July 1990 and July 2004. The study population comprised 185 females and 81 males, with a median age of 55 years (range, 20–90 years). Of the total, 223 patients were treated in institutions that include more than 30 patients. The primary tumor origins of the carcinomatosis were ovarian cancer 93, pseudomyxoma of appendiceal origin 65, colon cancer 51, primary abdominal mesothelioma 27, gastric cancer 20, uterus 6
Conclusions
From the study of the database which draws on the cases reported by the 9 Spanish centers interested in the implementation and development of this treatment program for peritoneal carcinomatosis, it can be concluded that considering cancer management as a national problem few centers are at present offering this type of treatment, with experiences that are limited in time and number of cases. There is a progressive increase in interest that can be detected and there are already more than 6
References (10)
- et al.
Peritoneal carcinomatosis in nongynecological malignancy: a prospective study of prognostic factors
Cancer
(1989) - et al.
Diffuse and gross peritoneal carcinomatosis treated by intraperitoneal hyperthermic chemoperfusion
- et al.
Peritoneal carcinomatosis from nongynecological malignancies: results of the EVOCAPE 1 multicentric prospective study
Cancer
(2000) - et al.
Peritoneal carcinomatosis from colorectal cancer
Br J Surg
(2002) - et al.
Prospective, randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer
Surgery
(1985)
Cited by (16)
Heterogeneous activity of cytotoxic drugs in patient samples of peritoneal carcinomatosis
2008, European Journal of Surgical OncologyCitation Excerpt :Peritoneal carcinomatosis (PC) was previously regarded as an incurable form of malignant disease with a poor prognosis, and the intention of treatment was palliative. However, results from several studies have shown that aggressive surgery, aimed at the removal of macroscopic tumour growth, followed by intraperitoneal chemotherapy (IPC), may produce prolonged long-term survival and even cure.1–6 The most recent development in the management of PC is the intraoperative use of hyperthermic intraperitoneal chemotherapy (HIPEC) based on in vitro findings of an increase in the efficacy of chemotherapy on tumour cells by increasing the temperature of the drug solution to approximately 42 °C.6–8
Organ-Specific Adverse Effects After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy
2022, Annals of Surgical OncologySystematic Review of Factors Affecting Quality of Life After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy
2020, Annals of Surgical OncologyNeoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: A feasibility and safety study
2019, World Journal of Surgical Oncology